Belgian start-up garners $15M in VC

Belgian start-up ActoGenix has raised $15 million in venture capital. The transaction was co-led by GIMV and Life Sciences Partners, with Biotech Fund Flanders also participating. ActoGeniX is a spin-off from the Flanders Interuniversity Institute of Biotechnology and Ghent University and was founded last June with seed capital from GIMV, VIB and individuals of the management team. It's a platform company, with drug research based on TopAct, a "delivery system comprising living non-pathogenic micro-organisms for the oral administration of biopharmaceuticals."

- see the release on the start-up

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.